SAN FRANCISCO – The name of the game thus far for Guardant Health Inc. has been precision medicine, using genomics to select the best therapy particularly for advanced cancer patients. But it's moving further into cancer recurrence monitoring – and even, ultimately, the Holy Grail of a liquid biopsy for cancer screening.